Patents Assigned to Millennium Pharmaceuticals, Inc.
  • CCR1 antagonists and methods of use thereof
    Patent number: 9334283
    Abstract: The invention provides compounds having the formula: wherein R1 is halogen. The invention also provides compositions comprising the compounds, and methods of treating diseases or disorders that comprise administering one or more of the compounds to a subject in need thereof. The disclosed compounds have CCR1 antagonist activity.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: May 10, 2016
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Kenneth G. Carson, Geraldine C. B. Harriman, Shomir Ghosh
  • Substituted hydroxamic acids and uses thereof
    Patent number: 9321731
    Abstract: This invention provides compounds of formula (I): wherein R1, R2, G, m, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: April 26, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Jeffrey P. Ciavarri, Kenneth M. Gigstad, He Xu
  • Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
    Patent number: 9290500
    Abstract: Disclosed are chemical entities that inhibit ubiquitin-activating enzyme (UAE), each of which is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein Y is and W, Z, XY, RY1, RY2 and RY3 are defined herein; pharmaceutical compositions comprising the chemical entities; and methods of using the chemical entities. These chemical entities are useful for treating disorders, particularly cell proliferation disorders, including cancers.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: March 22, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Roushan Afroze, Indu T. Bharathan, Jeffrey P. Ciavarri, Paul E. Fleming, Jeffrey L. Gaulin, Mario Girard, Steven P. Langston, Francois Soucy, Tzu-Tshin Wong, Yingchun Ye
  • Anti-GCC antibody molecules and methods for use of same
    Patent number: 9273146
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: March 1, 2016
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Helen A. Frank, Alice Mcdonald, Theresa L. O'Keefe
  • HYDROCHLORIDE SALT OF((1S,2S,4R)-4--2-HYDROXYCYCLOPENTYL) METHYL SULFAMATE
    Publication number: 20160030432
    Abstract: Disclosed is a compound of formula (I): crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an E1 activating enzyme, particularly NAE, including, e.g., cancer.
    Type: Application
    Filed: October 9, 2015
    Publication date: February 4, 2016
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ian G. Armitage, Reenu Chopra, Martin Ian Cooper, Marianne Langston, Steven P. Langston, Stepan Vyskocil
  • Use of inhibitors of I?B kinase for the treatment of cancer
    Patent number: 9248124
    Abstract: The present invention provides inhibitors of I?B kinase of general formula (I). or a stereoisomer or physiologically tolerable salt thereof, for use in the inhibition of the growth of a multiple myeloma cell and for use in the treatment of multiple myeloma, wherein R1-R8 and B6-B9 are described in the specification.
    Type: Grant
    Filed: November 6, 2002
    Date of Patent: February 2, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Julian Adams, Kenneth C. Anderson
  • Substituted hydroxamic acids and uses thereof
    Patent number: 9249142
    Abstract: This invention provides compounds of formula (I): wherein R1a, R1b, R1c, R1d, R2a, R2b, X1, X2, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: February 2, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Kenneth M. Gigstad, He Xu
  • HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME
    Publication number: 20160009744
    Abstract: Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra?, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.
    Type: Application
    Filed: June 30, 2015
    Publication date: January 14, 2016
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Matthew O. Duffey, Dylan England, Scott Freeze, Zhigen Hu, Steven Langston, Charles McIntyre, Hirotake Mizutani, Koji Ono, He Xu
  • Proteasome inhibitors and methods of using the same
    Patent number: 9233115
    Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: January 12, 2016
    Assignee: Millennium Pharmaceuticals Inc.
    Inventors: Raffaella Bernardini, Alberto Bernareggi, Paolo G. Cassara, Sankar Chatterjee, Germano D'Arasmo, Sergio De Munari, Edmondo Ferretti, Mohamed Iqbal, Ernesto Menta, Patricia A. Messina McLaughlin, Ambrogio Oliva
  • Substituted hydroxamic acids and uses thereof
    Patent number: 9227951
    Abstract: This invention provides compounds of formula (I): wherein X1, X2, X3, R2, R4b, R1, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: January 5, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Kenneth M. Gigstad, He Xu
  • Methods of synthesizing pharmaceutical salts of a factor Xa inhibitor
    Patent number: 9221758
    Abstract: Novel methods of preparing a compound of Formula I which is an inhibitor of Factor Xa and its maleate salt, are described herein.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: December 29, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Robert M. Scarborough, James P. Kanter, Keiko Sujino, Sharique Sami Zuberi
  • PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS
    Publication number: 20150353555
    Abstract: The present invention provides processes and synthetic intermediates for the synthesis of 4-substituted ((1S,2S,4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates, which are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.
    Type: Application
    Filed: November 25, 2014
    Publication date: December 10, 2015
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
  • Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
    Patent number: 9187482
    Abstract: Disclosed is a compound of formula (I): crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an E1 activating enzyme, particularly NAE, including, e.g., cancer.
    Type: Grant
    Filed: May 13, 2010
    Date of Patent: November 17, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ian G. Armitage, Reenu Chopra, Martin Ian Cooper, Marianne Langston, Steven P. Langston, Stepan Vyskocil
  • Solid pharmaceutical compositions and processes for their production
    Patent number: 9173846
    Abstract: This invention provides novel solid pharmaceutical compositions and processes for the bulk production of said compositions. This invention also provides methods of using the pharmaceutical compositions in the treatment of cancer.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: November 3, 2015
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventor: Bhavishya Mittal
  • Antibodies which bind human CXCR3
    Patent number: 9163084
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: October 20, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Shixin Qin, Nasim Kassam, Walter Newman
  • Heteroaryl compounds useful as inhibitors of E1 activating enzymes
    Patent number: 9150525
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: October 6, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Stepan Vyskocil, Gabriel S. Weatherhead
  • Heteroaryls and uses thereof
    Patent number: 9139589
    Abstract: This invention provides compounds of formula IA or IB: wherein R1, R2, G1 and HY are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: September 22, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Masaaki Hirose, Steven P. Langston, Hirotake Mizutani, Stepan Vyskocil
  • Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
    Patent number: 9127011
    Abstract: This invention provides novel pharmaceutical compositions of the compound of formula (I): or a pharmaceutically acceptable salt thereof, that are suitable for the bulk production of an oral pharmaceutical dosage form; processes for the production of said oral pharmaceutical dosage form; and the use of the pharmaceutical composition for the treatment of patients suffering from or subject to diseases, disorders, or conditions involving cell survival, proliferation and migration, including chronic inflammatory proliferative disorders, proliferative ocular disorders, benign proliferative disorders, and cancer.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: September 8, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Vijayalakshmi Ramanan, Irene S. Tobias, Raymond D. Skwierczynski, Dauntel S. Verwijs
  • Benzamides and related inhibitors of factor Xa
    Patent number: 9108922
    Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: August 18, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Wenrong Huang
  • Compounds and methods for inhibiting mitotic progression
    Patent number: 9102678
    Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: August 11, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead